DD156082A5 - Verfahren zur herstellung von aktivem chondroitinsulfat - Google Patents

Verfahren zur herstellung von aktivem chondroitinsulfat Download PDF

Info

Publication number: DD156082A5
Authority: DD; German Democratic Republic
Prior art keywords: active; patients; csa; starting material; chondroitin sulfate
Prior art date: 1980-02-04

Application number

DD22742781A

Other languages

German (de)

English (en)

Inventor

Perry G Rucker

Original Assignee

Biomed Res Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-02-04

Filing date

1981-02-04

Publication date

1982-07-28

1980-02-04 Priority claimed from US06/118,211 external-priority patent/US4302577A/en

1981-02-04 Application filed by Biomed Res Inc filed Critical Biomed Res Inc

1982-07-28 Publication of DD156082A5 publication Critical patent/DD156082A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 33
229920001287 Chondroitin sulfate Polymers 0.000 title claims abstract description 15
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 title claims abstract description 11
229940059329 chondroitin sulfate Drugs 0.000 title claims abstract description 10
230000008569 process Effects 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims abstract description 4
239000008139 complexing agent Substances 0.000 claims abstract description 12
239000007858 starting material Substances 0.000 claims abstract description 11
239000000243 solution Substances 0.000 claims abstract description 10
239000002244 precipitate Substances 0.000 claims abstract description 9
210000001519 tissue Anatomy 0.000 claims abstract description 7
239000007864 aqueous solution Substances 0.000 claims abstract description 4
210000000845 cartilage Anatomy 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims abstract description 4
241000251468 Actinopterygii Species 0.000 claims abstract description 3
150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract 2
230000015572 biosynthetic process Effects 0.000 claims description 5
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
239000000076 hypertonic saline solution Substances 0.000 claims description 2
239000011347 resin Substances 0.000 claims description 2
229920005989 resin Polymers 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
125000000129 anionic group Chemical group 0.000 claims 1
238000010409 ironing Methods 0.000 claims 1
241000283690 Bos taurus Species 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 4
239000000463 material Substances 0.000 abstract description 4
239000011149 active material Substances 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
206010047249 Venous thrombosis Diseases 0.000 description 16
239000000902 placebo Substances 0.000 description 16
229940068196 placebo Drugs 0.000 description 16
206010051055 Deep vein thrombosis Diseases 0.000 description 15
230000006872 improvement Effects 0.000 description 12
108010049003 Fibrinogen Proteins 0.000 description 11
102000008946 Fibrinogen Human genes 0.000 description 11
229940012952 fibrinogen Drugs 0.000 description 11
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
206010033425 Pain in extremity Diseases 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
208000007536 Thrombosis Diseases 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000003814 drug Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
108090000190 Thrombin Proteins 0.000 description 6
230000017531 blood circulation Effects 0.000 description 6
244000309466 calf Species 0.000 description 6
230000015271 coagulation Effects 0.000 description 6
238000005345 coagulation Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000002980 postoperative effect Effects 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
229960004072 thrombin Drugs 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
206010053567 Coagulopathies Diseases 0.000 description 5
230000002146 bilateral effect Effects 0.000 description 5
235000019504 cigarettes Nutrition 0.000 description 5
230000035602 clotting Effects 0.000 description 5
230000008859 change Effects 0.000 description 4
230000009089 cytolysis Effects 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
206010022562 Intermittent claudication Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010046996 Varicose vein Diseases 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000009806 oophorectomy Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000000391 smoking effect Effects 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
208000027185 varicose disease Diseases 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 2
241000251730 Chondrichthyes Species 0.000 description 2
229920002567 Chondroitin Polymers 0.000 description 2
102100023804 Coagulation factor VII Human genes 0.000 description 2
206010069729 Collateral circulation Diseases 0.000 description 2
206010052895 Coronary artery insufficiency Diseases 0.000 description 2
108010023321 Factor VII Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
208000010378 Pulmonary Embolism Diseases 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
229960001927 cetylpyridinium chloride Drugs 0.000 description 2
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
208000024980 claudication Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940012413 factor vii Drugs 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000009802 hysterectomy Methods 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
229940055729 papain Drugs 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
230000002688 persistence Effects 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000002537 thrombolytic effect Effects 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
241000283153 Cetacea Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
241000219000 Populus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
230000008321 arterial blood flow Effects 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004182 chemical digestion Methods 0.000 description 1
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
235000019506 cigar Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002682 general surgery Methods 0.000 description 1
238000000227 grinding Methods 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000003090 iliac artery Anatomy 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
238000012332 laboratory investigation Methods 0.000 description 1
238000011545 laboratory measurement Methods 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
238000000554 physical therapy Methods 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
239000012286 potassium permanganate Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
239000002994 raw material Substances 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000779 smoke Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
238000007631 vascular surgery Methods 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
239000013598 vector Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

DD22742781A 1980-02-04 1981-02-04 Verfahren zur herstellung von aktivem chondroitinsulfat DD156082A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/118,211 US4302577A (en)	1979-10-05	1980-02-04	Process for preparing CSA or CSC

Publications (1)

Publication Number	Publication Date
DD156082A5 true DD156082A5 (de)	1982-07-28

Family

ID=22377176

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD22742781A DD156082A5 (de)	1980-02-04	1981-02-04	Verfahren zur herstellung von aktivem chondroitinsulfat

Country Status (6)

Country	Link
AR (1)	AR224782A1 (fr)
AU (1)	AU6630781A (fr)
DD (1)	DD156082A5 (fr)
PL (1)	PL229502A1 (fr)
RO (1)	RO81186A (fr)
YU (1)	YU29681A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU604542B2 (en) *	1987-03-19	1990-12-20	Arthropharm Pty Ltd	Polysulphated polysaccharide complexes

1980
- 1980-10-03 AR AR28277280A patent/AR224782A1/es active
1981
- 1981-01-19 AU AU66307/81A patent/AU6630781A/en not_active Abandoned
- 1981-02-03 PL PL22950281A patent/PL229502A1/xx unknown
- 1981-02-04 DD DD22742781A patent/DD156082A5/de unknown
- 1981-02-04 RO RO81103300A patent/RO81186A/fr unknown
- 1981-02-04 YU YU29681A patent/YU29681A/xx unknown

Also Published As

Publication number	Publication date
PL229502A1 (fr)	1982-02-01
RO81186B (ro)	1983-01-30
YU29681A (en)	1983-09-30
AR224782A1 (es)	1982-01-15
RO81186A (fr)	1983-02-01
AU6630781A (en)	1981-08-13

Publication	Publication Date	Title
DE69106549T2 (de)	1995-06-22	Thrombin-Zusammensetzung zur oralen Verabreichung.
US4167562A (en)	1979-09-11	Method and composition for treating arteriosclerosis
EP0130550A2 (fr)	1985-01-09	Composition pharmaceutique à base de l'héparine et de tensionactifs excerçant un effet sur les muqueuses de la bouche, du nez et/ou de la gorge
DD288094A5 (de)	1991-03-21	Verwendung von gamma-interferon zur behandlung von gefaessverengungen
DE3150318C2 (de)	1983-10-20	"Verfahren zur Herstellung eines Polysaccharidderivats des Fibrinolysins"
DE3037299A1 (de)	1981-04-16	Verfahren zur herstellung von chondroitinsulfat
DE3937607A1 (de)	1991-05-16	Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
AT391315B (de)	1990-09-25	Verfahren zur herstellung von isosilybinfreiem silibinin
DE2745695A1 (de)	1978-04-13	Pharmazeutische kombination, verfahren zu ihrer herstellung und ihre verwendung
DE2823174A1 (de)	1979-01-25	Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose
CH639854A5 (de)	1983-12-15	Gefriergetrocknetes natives gammaglobulin-praeparat zur intravenoesen verabreichung und verfahren zu seiner herstellug.
DE2417859A1 (de)	1974-10-24	Verfahren zur herstellung von gemischten heparinsalzen
DE2453113A1 (de)	1975-05-15	5-(hydroxy-3-tert.-butylamino)-propoxy-3,4-dihydro-2-hydroxychinolin enthaltende arzneipraeparate
DE69109676T2 (de)	1996-02-08	Verminderung von kardiovaskulären gefässverschlüssen mit ascorbat und hemmstoffen der bindung von lipoprotein (a).
DE3306944C2 (fr)	1989-04-13
DE3779842T2 (de)	1992-12-24	Antiallergisches mittel.
WO1992019245A1 (fr)	1992-11-12	Utilisation du torasemide pour le traitement d'oedemes cerebraux
DE2037942C2 (de)	1982-11-18	Arzneimittel enthaltend ein "aktives" Chondroitinsulfat als Wirkstoff zur Verhinderung des Auftretens atherosklerotischer Läsionen und zur Verhinderung des Auftretens von Herzanfällen
DE1668171A1 (de)	1974-08-29	Verfahren zur herstellung von stabilen waessrigen loesungen neuer komplexer organosiliciumverbindungen
DD156082A5 (de)	1982-07-28	Verfahren zur herstellung von aktivem chondroitinsulfat
DE2117057C3 (de)	1980-07-31	Verfahren zur Herstellung eines Arzneimittels zur Behandlung von Augenkrankheiten
DE2349186C2 (de)	1982-11-11	Arzneimittel zur Verbesserung der Zellatmung, der Herzmuskelleistung und der Hirnfunktion
DE2550011A1 (de)	1977-05-12	Antihaemophiles mittel und verfahren zu dessen herstellung
DE2246969C2 (de)	1986-12-11	Urokinase-Heparinat und dieses enthaltende Arzneimittel
DE1802386C2 (de)	1984-02-02	Verfahren zur Gewinnung von cytobiotischen Globulinen